Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00095381
Status:
COMPLETED
Last Update Posted:
2012-01-19
First Post:
2004-11-03
Brief Title:
Repeat-Dose of Forodesine Hydrochloride BCX-1777 Infusion in Patients With Advanced T-Cell Leukemia
Sponsor:
BioCryst Pharmaceuticals
Organization:
BioCryst Pharmaceuticals
Study Overview
Official Title:
A Phase II Multi-Center Open-Label Repeat-Dose of Forodesine Hydrochloride BCX-1777 Infusion in Patients With Advanced T-Cell Leukemia With an Option of Long-Term Forodesine Hydrochloride BCX-1777 Use
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia
Patients will receive an infusion of BCX-1777 on days 1-5 Treatment may be repeated every week for up to six courses Patients are not required to be hospitalized for the administration of BCX-1777 Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks
Patients will receive an infusion of BCX-1777 on days 1-5 Treatment may be repeated every week for up to six courses Patients are not required to be hospitalized for the administration of BCX-1777 Some patients may continue to receive an infusion of BCX-1777 twice a week for 6 weeks
Detailed Description:
BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth The Phase II trial is designed to study the effectiveness of BCX-1777 in treating patients who have recurrent or refractory advanced T-cell leukemia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None